Publication | Closed Access

Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results

Metabolic SyndromeHepatologyLiver PhysiologyFibrotic NashPharmacologyPathologyHepatotoxicityPharmacotherapyHepatic FatLiver DiseaseHepatology FibrosisFatty Liver DiseaseMedicinePotent Fxr AgonistDrug-induced Liver InjuryHealth Sciences